^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FGFR2 overexpression

    i
    Other names: FGFR2, BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25, Fibroblast growth factor receptor
    Entrez ID:
    2263
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    6d
    FGFR2 is a Candidate Immune-Associated Marker of Diabetic Foot Ulcer That Promotes Keratinocyte Function by Activating the PI3K/Akt and MAPK Pathways. (PubMed, Mediators Inflamm)
    FGFR2 is lowly expressed in DFU and can exert a protective effect by activating the PI3K/Akt pathway. It is a candidate diagnostic biomarker and potential therapeutic target for DFU.
    Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    FGFR2 overexpression
    |
    Nerlynx (neratinib) • LY294002 • SB202190
    1m
    Comparison of the Efficacy of 35 Anticancer Drugs According to Genomic Profiling and Biological Characteristics of 14 Gastric Cancer Cell Lines. (PubMed, Int J Mol Sci)
    This study provides a framework for selecting cell lines that are responsive to each of the 35 anticancer drugs and elucidating their underlying therapeutic mechanisms through follow-up studies. Ultimately, clinical studies are required to confirm the therapeutic efficacy of the selected drugs.
    Clinical • Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • FGFR2 (Fibroblast growth factor receptor 2) • CLDN18 (Claudin 18) • CDK12 (Cyclin dependent kinase 12) • CD44 (CD44 Molecule) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    PD-L1 overexpression • HER-2 overexpression • MET overexpression • FGFR2 overexpression
    2ms
    WJOG18524G: a single-arm phase II study evaluating bemarituzumab combined with ramucirumab and paclitaxel in fibroblast growth factor receptor 2b (FGFR2b)-positive advanced gastric or gastroesophageal junction cancer (RAINBIRD). (PubMed, ESMO Gastrointest Oncol)
    The primary endpoint is the objective response rate, which is assessed by a blinded independent central review. Translational research is planned to explore the predictive biomarkers and mechanisms of resistance to bemarituzumab by sequencing tumor DNA (PleSSiSion-Neo) and circulating tumor DNA (Guardant360), which are collected at multiple time points.
    P2 data • Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    FGFR2 overexpression
    |
    Guardant360® CDx
    |
    paclitaxel • Cyramza (ramucirumab) • bemarituzumab (AMG 552)
    3ms
    FORTITUDE-301: A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (clinicaltrials.gov)
    P1/2, N=260, Completed, Amgen | Active, not recruiting --> Completed
    Trial completion • Pan tumor
    |
    FGFR2 overexpression
    |
    bemarituzumab (AMG 552)
    3ms
    BEMAFLOT: Study Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2-T4a or N+ Gastric and GEJ Adenocarcinoma Overexpressing FGFR2b (clinicaltrials.gov)
    P2, N=0, Withdrawn, Institut Cancerologie de l'Ouest | N=49 --> 0 | Trial completion date: Jun 2034 --> Jan 2026 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2029 --> Jan 2026
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    FGFR2 overexpression
    |
    docetaxel • oxaliplatin • bemarituzumab (AMG 552)
    5ms
    FORTITUDE-103: A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. (clinicaltrials.gov)
    P1/2, N=72, Active, not recruiting, Amgen | Trial completion date: Mar 2028 --> Aug 2026
    Trial completion date
    |
    FGFR2 overexpression
    |
    Opdivo (nivolumab) • capecitabine • oxaliplatin • bemarituzumab (AMG 552)
    5ms
    Association between FGFR2b Positivity and Survival Outcomes of Patients with Gastric Cancer Treated with First-Line Nivolumab Plus Chemotherapy. (PubMed, Cancer Res Treat)
    FGFR2b expression exhibits substantial intratumoral heterogeneity in gastric cancer and may be linked to favorable outcomes in patients undergoing first-line ICI plus chemotherapy. Therefore, future studies should validate this finding, along with mechanistic investigations.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    FGFR2 overexpression
    |
    Opdivo (nivolumab)
    6ms
    Correlation and Overlap Between Claudin 18.2 and FGFR2b Overexpression: A Tissue Microarray Study With 1,538 Gastric Carcinomas. (PubMed, J Gastric Cancer)
    CLDN18.2 and FGFR2b were significantly associated with each other, suggesting a considerable overlap. This finding may have important clinical implications on the optimal treatment strategy for CLDN18.2-positive GC.
    Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    CLDN18.2 positive • FGFR2 overexpression
    7ms
    High FGFR4 protein expression, but not FGFR1 or FGFR2, predicts poor prognosis in pancreatic ductal adenocarcinoma. (PubMed, BMC Cancer)
    FGFR4 showed the strongest prognostic association among the FGFR family members studied, with high protein expression correlating with shorter disease-free survival in PDAC patients. These findings underscore the potential of FGFR4 as a biomarker for recurrence risk, while also highlighting the complexity of FGFR-related signaling and its context-dependent clinical relevance.
    Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR4 (Fibroblast growth factor receptor 4)
    |
    FGFR2 fusion • FGFR2 overexpression
    7ms
    FORTITUDE-103: A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. (clinicaltrials.gov)
    P1/2, N=72, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting | Trial completion date: Aug 2028 --> Mar 2028 | Trial primary completion date: Jun 2026 --> Jan 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    FGFR2 overexpression
    |
    Opdivo (nivolumab) • capecitabine • oxaliplatin • bemarituzumab (AMG 552)
    over1year
    FGFR2-RUNX2 activation: An unexplored therapeutic pathway in luminal breast cancer related to tumor progression. (PubMed, Int J Cancer)
    Our findings suggest a complex interplay between FGFR2 and RUNX2 in regulating tumor aggressiveness. This study underscores the significance of RUNX2 in luminal BrCa progression and posits RUNX2 as a promising therapeutic target and as a potential prognostic biomarker in luminal BrCa patients.
    Journal • BRCA Biomarker
    |
    FGFR2 (Fibroblast growth factor receptor 2) • CBFB (Core-Binding Factor Subunit Beta 2) • RUNX2 (RUNX Family Transcription Factor 2)
    |
    FGFR2 overexpression
    over1year
    A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201) (clinicaltrials.gov)
    P1, N=74, Terminated, Amgen | Completed --> Terminated; Business decision not due to safety concerns
    Trial termination
    |
    KRAS (KRAS proto-oncogene GTPase) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    KRAS mutation • KRAS G12C • KRAS G12 • FGFR2 overexpression • FGFR2b overexpression
    |
    Keytruda (pembrolizumab) • carboplatin • docetaxel • albumin-bound paclitaxel • bemarituzumab (AMG 552)